BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...

Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 ...

BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Mainz, Germany, January 12, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will provide a strategic business update and outline the Company’s focus areas for 2026, including an ...

An update from BioNTech SE ( ($BNTX) ) is now available. On January 6, 2026, BioNTech SE reported that CureVac N.V. had completed a previously ...

Biopharma companies—including AstraZeneca, BioNTech and Agios—peered farther into the future on the second day of JPM, ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual ...

A key enabler for BioNTech's ambitious plans is an exceptionally strong balance sheet, rare for a biotechnology company. As of the end of 2025, the Mainz-based firm reported liquid funds of ...

Through seed and Series A investment, the fund supports projects developing novel therapeutics, diagnostics, research tools, ...

BioNTech, a pioneer in mRNA-based medicines and next-generation immunotherapies, has longstanding scientific and translational ties to Penn. Through the PxB Fund, BioNTech aims to deepen its ...

The University of Pennsylvania, biotech firm BioNTech, and Osage University Partners, a venture capital firm in Bala Cynwyd, ...